WHO Sounds Warning Over Acute Lack of Weight-Loss Jabs

Under a tenth of individuals that would benefit from GLP-1 drugs such as Wegovy can access them, states the World Health Organization as it issues its first guidance on the medications.

Given over a billion people worldwide currently obese, it is advocating for increased and just availability to GLP-1 medication.

According to forecasts, over two billion could be living with obesity by 2030 if no action is taken.

"The new guidelines affirms that obesity is a chronic disease that can be treated with thorough and ongoing treatment," stated the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and logistical bottlenecks are key barriers to broad access to the jabs that can assist patients in reducing substantial weight, explains the organization.

Weight-Loss Drug Scarcity

Despite the current most favorable outlook, the supply of such drugs could only cover approximately 100 million people – fewer than 10% of eligible patients, per the WHO.

The guideline calls on countries and companies to increase access, by measures such as licensing agreements.

A patent on a key compound – the main component of a leading brand – is due to expire in a number of nations in 2026.

The Way Obesity Jabs Operate

These medications replicate a natural hormone to slow digestion, reduce hunger and enhance feelings of fullness so individuals eat less.

Patients usually start to lose weight within a few weeks of commencing the weekly injections.

Evidence points to people may see weight return after a year of halting the medication, as their typical food cravings resume.

Being above a healthy weight raises your likelihood for experiencing health problems, including diabetes, cardiovascular issues, brain attack, and specific cancers.

Excess weight affects people in all nations and was linked to over three and a half million fatalities worldwide in 2024, as per the health agency.